Via practica 2/2020
Dyslipidemia and diabetic foot syndrome
Patients with diabetic foot syndrome represent a high-risk group not only due to the risk of limb amputation, but also because of their high cardiovascular mortality. To reduce their cardiovascular risk it is necessary to make use of all available treatment options, including adequate lipid-lowering therapy. This therapy can also positively affect the emergence and development of own diabetic foot, taking a decision on specific drugs should take into account dominant ethiopathogenesis of the disease.
Keywords: diabetic foot, dyslipidemia, neuropathy, peripheral artery disease, statins, fibrates, ezetimibe, PCSK9-inhibitors
